key: cord-0893468-623hsjon
authors: Gago, Juan; Thomas, D Filardo; Conderino, Sarah; Magaziner, Samuel J; Dubrovskaya, Yanina; Inglima, Kenneth; Iturrate, Eduardo; Pironti, Alejandro; Schluter, Jonas; Cadwell, Ken; Hochman, Sarah; Li, Huilin; Torres, Victor J; Thorpe, Lorna E; Shopsin, Bo
title: Pathogen Species is Associated With Mortality in Nosocomial Bloodstream Infection in Patients with COVID-19
date: 2022-04-05
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac083
sha: d7063b028503b84b130eff136a217010c1ab72a1
doc_id: 893468
cord_uid: 623hsjon

BACKGROUND: The epidemiology of nosocomial bloodstream infections (NBSI) in patients with coronavirus disease 2019 (COVID-19) is poorly understood, due in part to substantial disease heterogeneity resulting from multiple potential pathogens. METHODS: We identified risk factors for NBSI and examined the association between NBSI and mortality in a retrospective cohort of patients hospitalized with COVID-19 in two New York City hospitals during the pandemic height. We adjusted for the potential effects of factors likely to confound that association, including age, race, illness severity upon admission and underlying health status. RESULTS: Between January 1-October 1, 2020, 1403 patients had a positive blood culture, 79 and 101 met stringent criteria of NBSI among non-COVID-19 and COVID-19 patients, respectively. NBSI occurred almost exclusively among patients who were severely ill with COVID-19 at hospital admission. NBSI were associated with elevated mortality, even after adjusting for baseline differences in COVID-19 illness (55% cases vs 45% controls,p= 0.13). Mortality was concentrated in patients with early onset pneumonia caused by S. aureus and Gram-negative bacteria. Less virulent Candida (49%) and Enterococcus (12%) species were the predominant cause of NBSI in the latter stages of hospitalization, after antibiotic treatment and COVID-19 treatments that attenuate immune response. Most Enterococcus and Candida infections did not have an identifiable source and were not associated with common risk factors for infection by these organisms. CONCLUSIONS: Pathogen species and mortality exhibited temporal differences. Early recognition of risk factors among COVID-19 patients could potentially decrease NBSI-associated mortality through early COVID-19 and antimicrobial treatment.

Since the pandemic onset, coronavirus disease (COVID-19) mortality rates in US hospitals have declined owing to increasing experience with the disease, decreased patientto-caregiver ratios, new treatments, and vaccination [1] [2] [3] [4] . However, vaccine hesitancy, along with the emergence of new viral variants could undo such progress 5 . Better understanding of factors associated with poor COVID-19 outcomes could reduce vulnerability during recurrent COVID-19 outbreaks and build resilience against future pandemic pathogens.

Bloodstream infections (BSI) are among the most serious medical complications in COVID-19 patients [6] [7] [8] [9] [10] . Recent work by us and others suggests that gut microbiome dysbiosis is associated with bacterial translocation into the blood during COVID-19 11,12 . Consistent with this idea, a high frequency of Candida and Enterococcus species BSI has been described among hospitalized COVID-19 patients 13-15 -a finding otherwise seen primarily in patients with dysbiosis from cancer treatment in which these microbes translocate from the gut [16] [17] [18] . The natural history of BSI is poorly defined, in part because of substantial disease heterogeneity resulting from multiple potential pathogens, sites of infection, and the clinical time course of COVID-19.

In March 2020, New York City emerged as an epicenter of the COVID-19 pandemic 19 . To explore relationships between COVID-19, BSI risk, and mortality, we assembled a retrospective cohort of COVID-19 patients to study BSI epidemiology using both matched and unmatched controls. We excluded patients having a SARS-CoV-2positive PCR test result but non-COVID illness. We focused on nosocomial BSI (NBSI) because nosocomial infection, rather than co-infection upon hospital admission, is the primary threat to COVID-19 patients 20 . We also excluded skin microbiota from the analysis (e.g., coagulase-negative staphylococci, Bacillus), because skin microbiota can represent a high proportion of contaminants in overstretched hospitals managing many A c c e p t e d M a n u s c r i p t 6 patients 21 , and these organisms may not contribute to mortality 22 . These stringent criteria enabled us to examine temporal trends between COVID-19 and NBSI.

We screened for NBSI among all adult COVID-19 patients admitted to two New York University Langone Health (NYULH) hospitals-one that serves an affluent population (Manhattan), and one that serves an underserved population (Brooklyn). Floor beds are able to provide intensive care unit (ICU)-level care; consequently, both floors and ICUs managed critically ill patients.

To determine the impact of NBSI on mortality, we compared COVID-19 patients with recorded NBSI to COVID-19 patients with no record of BSI. To establish a more comparable control group, we generated a subset of matched COVID-19 patients with no record of NBSI using propensity score matching 23 .

Patient data were extracted from electronic health records and manual chart review.

We obtained data on baseline clinical characteristics (within 72 h of admission) and underlying comorbidities. Oxygen use was categorized as follows: none (no supplementary oxygen), low oxygen (low-flow non-invasive supplementary devices), high oxygen (highflow), non-invasive ventilation (Bi-PAP, CPAP), and invasive ventilation (intubated). Timevarying data (e.g., steroid use) were collected from admission date forward.

Cases were defined as all patients with a COVID-19 diagnosis at the time of admission, a positive SARS-CoV-2 PCR result, and a positive blood culture obtained >48 h A c c e p t e d M a n u s c r i p t 7 after admission to the hospital (Fig. 1) . Infectious disease consultation notes, admission and primary team notes, and discharge summaries were reviewed by two infectious diseases physicians (T.D.F. and B.S.) to verify (1) acute COVID-19 was the primary reason for hospitalization, 2) nosocomial onset of BSI (e.g., no signs/symptoms of BSI at the time of hospital admission), and 3) presumed source of NBSI 24 A c c e p t e d M a n u s c r i p t 8

Pearson χ 2 test was used to compare microorganism frequencies. To examine the independent effect of NBSI on mortality, we first created a predictive model of NBSI that included the following set of potentially confounding variables: age, race, illness severity upon admission (e.g., supplemental oxygen) and underlying health status (Charlson Comorbidity index) 28-30 using the complete COVID19 cohort. We then calculated the estimated propensity score for each subject using nearest neighbor propensity score matching (4 controls per case) to identify a NBSI-negative control group 31 . To evaluate the covariate distribution for the unmatched and matched groups, standardized differences were calculated. We also determined the effect of COVID-19 treatments prior to the positive blood culture (e.g., steroids, IL-6 inhibitors) on NBSI risk and mortality.

Kaplan-Meier curves were used to present mortality risk over time. Log-rank tests accounting for matched pairing were used to test the group difference in mortality risk. We ran a Cox proportional hazard model, matching between cases and their respective controls and adjusting for covariates, including type of microorganism (using ‗none' as a control), age, and sex. We tested the assumption of proportionality using function ‗cox.zph()' in R package ‗survival'. We also performed an accelerated failure time model, which does not require such stringent assumptions, using the Weibull distribution to evaluate survival time 32 .

Time ratios (TRs) and 95% confidence intervals (CIs) were calculated to assess percent change in survival time (100% * [TR-1]). Logistic regression was used to estimate odds ratios of NBSI onset for different treatments. All statistical analyses were performed in R 

Between January 1-October 1, 2020, 1403 inpatients had a positive blood culture. We excluded 606 patients with cultures positive for microorganisms likely to be contaminants or low virulence pathogens (Fig. 1) 

Among the 101 COVID-19 patients with NBSI, Candida (49%) and Enterococcus (12%) were the leading pathogens ( Table 1 ). The proportion of BSIs that were due to Candida (Fig. 2 A c c e p t e d M a n u s c r i p t

To determine whether COVID-19 patients are more likely than non-COVID-19 patients to have Candida and Enterococcus BSI, we compared clinical characteristics between patients from two time periods: 1) BSI without COVID-19 from February 15-December 31, 2020, or 2) hospitalized for any reason from January 1-December 31, 2019 (historical non-COVID-19 cohort) ( Table 1 ). The historical non-COVID-19 cohort consisted of 117 control cases with NBSI from 2019 out of 1390 patients with positive blood cultures.

We excluded 581 cases due to potentially contaminating or clinically insignificant organisms and 691 that occurred < 48 h after hospital admission.

The prevalence of Candida was more than two times higher in COVID-19 patients than in patients belonging to either control group ( Table 1) . We did not find significant differences of Enterococcus BSI frequencies. However, among patients with NBSI due to Candida or Enterococcus (Table S1) , there were significant differences between COVID-19 cases and non-COVID-19 controls in the 2020 cohort in known risk factors for infection by these organisms, the latter having more gastrointestinal surgeries, active malignancies, chemotherapy and higher Charlson Index Score. Gram-negative bacteria were more abundant among non-COVID-19 controls. The abundance of Candida and Enterococcus in the absence of obvious risk factors suggests that Candida and Enterococcus represent distinct complications of COVID-19.

Candida and Enterococcus causing NBSI in COVID-19 patients were recovered from the urine or sputum in only 4 of 62 instances (6%). COVID-19 patients with NBSI were more likely to have a central venous catheter (CVC) than controls (Table S1). Less than 5% were associated with femoral catheters, which are highest risk for BSI.

In contrast to NBSI with Candida and Enterococcus, where few patients had these organisms isolated from sites other than blood, COVID-19 patients with S. aureus or Gramnegative NBSI had the same organisms recovered in respiratory cultures in 7 of 9 (77%) and A c c e p t e d M a n u s c r i p t 11 9 of 11 (80%) instances, respectively. NBSI in these cases most often occurred after endotracheal intubation, an important risk factor for bacterial pneumonia 33 . Indeed, all patients with S. aureus or Gram-negative NBSI developed clinical signs of pneumonia (e.g., fever, purulent secretions, radiology changes) and were treated for nosocomial pneumonia.

During the study period, we identified a control population of 3273 SARS-CoV-2 PCR test-positive patients without BSI that were admitted for COVID-19. Baseline inflammatory markers (e.g., C-reactive protein) were elevated in almost all patients ( Table 2) . COVID-19 patients with NBSI were substantially different from COVID-19 patients without NBSI before matching; patients with NBSI were younger, more likely to be male and Non-Hispanic white, required more oxygen at the time of hospitalization, and had different comorbidities.

Propensity score matching resulted in a well-balanced control group of 404 patients (SDS < 0.1 for all matching covariates). The number of patients requiring a ventilator at admission between groups was not significantly different (49.5% among cases versus 47.0 % among matched controls; SDS = 0.08). The absolute difference in in-hospital mortality risk between BSI (+) patients and BSI (-) unmatched patients was 31.5 % (54.5% vs 23.0%; 95% CI: 21.7% -40.9%). When compared to propensity-scored BSI (-) matched controls, mortality risk among those with NBSI remained higher by 9.5% (54.5% vs 45.0%), but the adjusted observed difference was not statistically significant, as confidence intervals were wide and overlapped (95% CI: 44.2% -64.4% vs 40.1%-50.0%). Thus, while NBSI may be associated with moderate increased risk of mortality risk in patients with COVID-19, we cannot rule out the possibility that the observed difference was due to chance.

Kaplan-Meier mortality curves for cases and matched controls indicated no overall difference between the two curves (Fig. 3a) . However, curves stratified by microorganism species (Fig. 3b) indicated that mortality was significantly concentrated in S. aureus and A c c e p t e d M a n u s c r i p t 12 Gram-negative NBSI early after hospitalization. Patients with Candida alone did not have a higher risk of mortality compared to those without NBSI. Thus, although Candida and Enterococcus were the predominant pathogens in NBSI, S. aureus and Gram-negative bacteria were possibly the most deadly.

COVID-19 positive patients were administered several types of antibiotics, antifungals, and immunosuppressive agents, namely steroids and the IL-6 inhibitor tocilizumab (the most commonly used IL-6 inhibitor at our institution). Sensitivity analyses using different treatments to stratify mortality revealed that tocilizumab significantly reduced mortality in both NBSI and non-NBSI COVID-19 patient groups (Fig. S1 ).

To define potential independent predictors of mortality, we initially compared COVID-19 NBSI and matched cases using an accelerated failure time (AFT) Weibull model using type of microorganism, age, and sex as covariates, as cases and the matched control group did not meet the assumption of proportionality required for Cox-PH modeling (p < 0.001).

Both the AFT model and the Cox-PH model (shown for comparative purposes) showed that patients with NBSI had a decreased survival time for all organisms except Candida.

Additionally, older age and male gender decreased survival ( Table 4) .

Gram-negative and S. aureus NBSI time ratios (TR) were shortened, the latter significantly (TR: 0.51 and 0.15, p: 0.22 , < 0.01 respectively). In contrast, the TR for 

Ceftriaxone, azithromycin, and hydroxychloroquine were widely prescribed among both cases and controls ( Table 3 ). In contrast, NBSI cases received tocilizumab and steroids, broad-spectrum antimicrobial (vancomycin, meropenem, and piperacillintazobactam), and antifungals (micafungin and fluconazole) more frequently. Thus, NBSI cases received more aggressive treatment than non-NBSI controls. We also analyzed the odds of developing NBSI linked to COVID-19 treatments using a univariate logistic model with NBSI as the outcome. Tocilizumab did not predict NBSI (Table S2) . However, patients treated with piperacillin-tazobactam, vancomycin, meropenem, and hydrocortisone had higher odds of having NBSI compared to those not receiving those treatments. infection and treatments targeting the COVID-19 hyperinflammatory state may fuel gut injury (e.g., steroids, IL-6 inhibitors) [34] [35] [36] [37] , and intestinal overgrowth under antimicrobial pressure is known to precede translocation of Candida and Enterococcus [16] [17] [18] . Finally, analysis of gut microbiota in patients with COVID-19 belonging to our study cohort shows that BSI is associated with gastrointestinal overgrowth by the same organisms 12 , as seen in patients undergoing allogeneic hematopoietic stem cell transplantation 17, 18 . Additionally, recent work demonstrates that COVID-19 patients have increased bacterial products 38 Our data also suggests that NBSI increases mortality; COVID-19 patients who developed NBSI had an increased risk of death compared to propensity matched controls.

However, while mortality between the COVID-19 patients with NBSI and matched controls without NBSI was not significant, the slope declined most precipitously in patients without NBSI. This finding could reflect survivor bias (patients must survive long enough to be classified as acquiring NBSI). However, patients without NBSI who died early were older and more frail than those with NBSI, which suggests a potential interaction between COVID-19 treatment and subsequent NBSI. In this scenario, treatment improves survival of otherwise healthy but critically ill COVID-19 patients but also might have negative consequences for immune and microbiota-based clearance mechanisms that control infection, thereby predisposing patients to NBSI. Consistent with this idea, length of stay and mortality were inversely correlated in COVID-19 patients with NBSI. This finding may explain why mortality does not increase with candidemia, which primarily occurred after a prolonged length of hospital stay. NBSI mortality was found to be significantly concentrated in patients with S. aureus and Gram-negative nosocomial pneumonia (NP). S. aureus NP is a frequent complication in mechanically ventilated COVID-19 patients [40] [41] [42] , and bacteremia is an independent risk factor for mortality in NP 43 . Evidently, COVID-19 and bacteremic NP is a combination that kills patients at high frequency.

The present work has several limitations. First, our observational cohort data were obtained from two hospitals during the pandemic surge; whether NBSI patterns predict outcome in different scenarios, such as in a partially vaccinated population, will need to be tested. Second, correlations between NBSI and outcome may reflect factors we did not account for, such as managing high numbers of critically unwell patients and digression from A c c e p t e d M a n u s c r i p t 16 infection prevention procedures. Third, use of clinical criteria and the T2Candida panel for the diagnosis of pneumonia and candidemia, respectively, may lead to overdiagnosis, potentially increasing the rate of overall disease detected and the proportion of pneumonia cases that may be linked to NBSI and mortality.

In conclusion, NBSI is associated with mortality in hospitalized patients with severe COVID-19, depending on the species. Our finding suggests that early recognition of risk factors and treatment of NBSI are indicated. However, without accurate predictors of NBSI to guide clinicians, increased use of active agents could further shift species from a preponderance of susceptible organisms to more frequent isolation of antibiotic-resistant and Candida species. Accordingly, improved prediction models, potentially using immunological and microbiota markers, are needed. Improved prediction of NBSI could decrease morbidity and mortality by increasing early antimicrobial treatment for COVID-19 patients at risk for BSI and by reducing unnecessary antimicrobials for patients at low risk of infection. M a n u s c r i p t c Defined as isolation of more than one microorganism from the blood within 72hrs.

d Defined as isolation of more than one microorganism from the blood after 72hrs.

A c c e p t e d M a n u s c r i p t 26 A c c e p t e d M a n u s c r i p t 

Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States

Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine -United States

Trends in COVID-19 risk-adjusted mortality rates

Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers

Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant

Risk factors and outcomes of hospitalized patients with severe coronavirus disease 2019 (COVID-19) and secondary bloodstream infections: A multicenter case-control study

Predominance of hospital-acquired bloodstream infection in patients with COVID-19 pneumonia

Bloodstream infections in critically ill patients with COVID-19

Hospital-acquired bloodstream infections in patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection (Coronavirus Disease 2019): Association with immunosuppressive therapies

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge

Plasma microbiome in COVID-19 subjects: an indicator of gut barrier defects and dysbiosis

Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation

Unexpectedly high frequency of enterococcal bloodstream infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study

The landscape of candidemia during the COVID-19 pandemic

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation

Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans

High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis

Introductions and early spread of SARS-CoV-2 in the New York City area

Bacterial coinfections in coronavirus disease 2019

Comparing proportional hazards and accelerated failure time models: an application in influenza

The impact of tracheal intubation on host defenses and risks for nosocomial pneumonia

Bowel ulceration following tocilizumab administration in a COVID-19 patient

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

Dexamethasone in hospitalized patients with Covid

SARS-CoV-2 productively infects human gut enterocytes

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus

Enterococcus, and healthcare-associated bloodstream infections: Results of a quasiexperimental multicenter trial

Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia

Early bacterial co-infection in ARDS related to COVID-19

Tocilizumab for rreatment of mechanically ventilated patients with COVID-19

Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia

Acknowledgments. We thank Karl Drlica, Robert Ulrich, and Jeffrey Weiser for critical comments on the manuscript. Patient consent. This study does not include factors necessitating patient consent.

A c c e p t e d M a n u s c r i p t 19